Sökning: onr:"swepub:oai:DiVA.org:uu-481063" > Evaluation in pig o...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05666naa a2200673 4500 | |
001 | oai:DiVA.org:uu-481063 | |
003 | SwePub | |
008 | 220802s2023 | |||||||||||000 ||eng| | |
009 | oai:research.chalmers.se:5ccbf665-2d57-4362-b788-dba72d65fa27 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4810632 URI |
024 | 7 | a https://doi.org/10.1016/j.jconrel.2022.12.0112 DOI |
024 | 7 | a https://research.chalmers.se/publication/5339152 URI |
040 | a (SwePub)uud (SwePub)cth | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Berg, Staffanu Uppsala universitet,Institutionen för farmaci,Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden,Uppsala University,AstraZeneca AB4 aut0 (Swepub:uu)stabe945 |
245 | 1 0 | a Evaluation in pig of an intestinal administration device for oral peptide delivery |
264 | 1 | b Elsevier,c 2023 |
338 | a print2 rdacarrier | |
520 | a The bioavailability of peptides co-delivered with permeation enhancers following oral administration remains low and highly variable. Two factors that may contribute to this are the dilution of the permeation enhancer in the intestinal fluid, as well as spreading of the released permeation enhancer and peptide in the lumen by intestinal motility. In this work we evaluated an Intestinal Administration Device (IAD) designed to reduce the luminal dilution of drug and permeation enhancer, and to minimize movement of the dosage form in the intestinal lumen. To achieve this, the IAD utilizes an expanding design that holds immediate release mini tablets and places these in contact with the intestinal epithelium, where unidirectional drug release can occur. The expanding conformation limits movement of the IAD in the intestinal tract, thereby enabling drug release at a single focal point in the intestine. A pig model was selected to study the ability of the IAD to promote intestinal absorption of the peptide MEDI7219 formulated together with the permeation enhancer sodium caprate. We compared the IAD to intestinally administered enteric coated capsules and an intestinally administered solution. The IAD restricted movement of the immediate release tablets in the small intestine and histological evaluation of the mucosa indicated that high concentrations of sodium caprate were achieved. Despite significant effect of the permeation enhancer on the integrity of the intestinal epithelium, the bioavailability of MEDI7219 was of the same order of magnitude as that achieved with the solution and enteric coated capsule formulations (2.5–3.8%). The variability in plasma concentrations of MEDI7219 were however lower when delivered using the IAD as compared to the solution and enteric coated capsule formulations. This suggests that dosage forms that can limit intestinal dilution and control the position of drug release can be a way to reduce the absorptive variability of peptides delivered with permeation enhancers but do not offer significant benefits in terms of increasing bioavailability. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinsk bioteknologix Biomaterialvetenskap0 (SwePub)304032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Medical Biotechnologyx Biomaterials Science0 (SwePub)304032 hsv//eng |
653 | a Oral peptide delivery | |
653 | a intestinal administration | |
653 | a sodium caprate | |
653 | a permeation enhancer | |
653 | a MEDI7219 | |
653 | a Biofarmaci | |
653 | a Biopharmaceutics | |
653 | a Galenisk farmaci | |
653 | a Pharmaceutics | |
700 | 1 | a Uggla, Teresiau AstraZeneca AB4 aut |
700 | 1 | a Antonsson, Malinu AstraZeneca AB4 aut |
700 | 1 | a Nunes, Sandro Filipeu AstraZeneca AB4 aut |
700 | 1 | a Englund, Mariau AstraZeneca AB4 aut |
700 | 1 | a Rosengren, Louiseu AstraZeneca AB4 aut |
700 | 1 | a Fahraj, Masoudu AstraZeneca AB4 aut |
700 | 1 | a Wu, Xiaoqiuu AstraZeneca AB4 aut |
700 | 1 | a Govender, Rydvikha,d 1989u AstraZeneca AB4 aut0 (Swepub:cth)rydvika |
700 | 1 | a Söderberg, Magnusu AstraZeneca AB4 aut |
700 | 1 | a Janzén, Davidu AstraZeneca AB4 aut |
700 | 1 | a Van Zuydam, Natalieu AstraZeneca AB4 aut |
700 | 1 | a Hugerth, Andreas4 aut |
700 | 1 | a Larsson, Anette,d 1966u Chalmers tekniska högskola,Chalmers University of Technology4 aut0 (Swepub:cth)anettel |
700 | 1 | a Bergström, Christel A. S.,d 1973-u Uppsala universitet,Institutionen för farmaci4 aut0 (Swepub:uu)cjo29958 |
700 | 1 | a Abrahamsson, Bertilu AstraZeneca AB4 aut |
700 | 1 | a Davies, Nigelu AstraZeneca AB4 aut |
700 | 1 | a Bergström, Christel A. S.,d 1973-u Uppsala universitet,Institutionen för farmaci4 aut0 (Swepub:uu)cjo29958 |
710 | 2 | a Uppsala universitetb Institutionen för farmaci4 org |
773 | 0 | t Journal of Controlled Released : Elsevierg 353, s. 792-801q 353<792-801x 0168-3659x 1873-4995 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-481063 |
856 | 4 8 | u https://doi.org/10.1016/j.jconrel.2022.12.011 |
856 | 4 8 | u https://research.chalmers.se/publication/533915 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy